Navigation Links
Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,,,Applications

m Taq DNA polymerase High Fidelity (Life Technologies, Inc.), a blend developed specifically for high-fidelity PCR applications, and the Expand 20 kbPlus PCR system (Roche Molecular Biochemicals), the only commercial blend specifically formulated for amplifications of extra-long (>20 kb) genomic targets. The range of amplicon lengths synthesized by each formulation was evaluated by amplifying a panel of short genomic DNA targets, ranging in length from 0.1 kb to 0.5 kb (Figure 1) and a panel of extra-long targets, ranging in length from 17 kb to 48 kb (Figure 2). Amplifications were performed under identical conditions (Methods) with the following exceptions: as per the manufacturers recommendations, PCRs were carried out using 2.5 U of Platinum Taq DNA polymerase High Fidelity, 2.6 U of Expand 20 kbPlus PCR system blend, and 2.5 U (<1 kb) or 5 U (>17 kb) of Herculase enhanced DNA polymerase. The 30-kb and 48-kb targets were amplified with the Herculase formulation in the presence of 3% and 7% DMSO, respectively.

Fig.2

The Platinum Taq DNA polymerase High Fidelity exhibited limited target-length capability compared to Herculase enhanced DNA polymerase, which successfully amplified all targets up to 48 kb in length (Figure 1 and Figure 2). Even in amplifications of short targets, the Herculase formulation produced higher product yields than the Platinum Taq blend (Figure 1). Although the Expand 20 kbPlus PCR system successfully amplified the longer 17-kb and 30-kb genomic targets, product yields were highest with the Herculase formulation. Moreover, amplification of the longest 4
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Efficiently Insert Unique Restriction Sites into Plasmid Vectors
2. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
3. A Unique Dimension in Biological Purity
4. Unique Histochemical Substrate Permits Dual Staining In Animal Tissue
5. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
6. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
7. Pfu DNA Polymerase as a Hot Start Alternative
8. PCR Performance Comparisons Between pfuturbo and Taq DNA Polymerases
9. pfuturbo DNA Polymerase: A High-Performance, High-Fidelity Enzyme Ideal for PCR Cloning
10. Enhanced Amplification of Long Targets with PfuTurbo DNA Polymerase
11. High-Fidelity PCR with a Novel Polymerase Mixture
Post Your Comments:
(Date:12/19/2014)... Biddeford, ME (PRWEB) December 18, 2014 ... founding director of the Center for Excellence in the ... of New England, has been selected as a member ... He is the first neuroscientist from Maine to receive ... a nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... The empty capsules market is experiencing ... and technological innovations in the empty capsules market. ... the growth of the empty capsules market. , ... Scope of Report , The report will enrich ... firms to gauge the pulse of the market ...
(Date:12/19/2014)... ISN has released its third annual U.S. ... series. With data aggregated from over eight billion U.S. ... online contractor management platform, ISNetworld, this three-part series provides ... The Contractor Performance Benchmarking ... in two industry specific volumes: Oil & Gas, ...
(Date:12/17/2014)... 2014 “Never say, ‘I cannot ... Marburg’s Department of Physics, advises young women pursuing ... released SPIE Women in Optics 18-month planner ... to ask questions.” , In the annual planner, ... occupations ranging from university professor and laboratory researcher ...
Breaking Biology Technology:UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... ... ... ... ...
... failure affects the surface of an individual heart muscle ... technique developed at Imperial College London. The findings may ... can slow the development of heart failure, and to ... and abnormal heart rhythms. Heart failure is ...
... ... molding, two-material molding and micro-molding for medical device components and assemblies, has promoted Greg ... ... single-source provider of silicone molding, two-material molding and micro-molding for medical device components and ...
Cached Biology Technology:Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 3Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 4Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 5Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 6Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 7Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 8Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 9Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 10Researchers gain detailed insight into failing heart cells using new nano technique 2Researchers gain detailed insight into failing heart cells using new nano technique 3Riemer Named President of Medical Device Manufacturer MRPC 2
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season ... industry as Acuity Market Intelligence reports that the ... be open. Acuity forecasts that intensifying demand for ... incorporate biometrics will drive a global market of ... devices by 2020.   According to ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - ... report to their offering. ... of AuthenTec in July 2012, Apple introduced the ... is currently the only device of Apple incorporating ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... the "Micro Market Monitor: North America Perimeter Security ... http://photos.prnewswire.com/prnh/20130307/600769 The North ... a CAGR of 3.6% from 2014 to 2019. Although ... market, Canada is expected to ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... pollen next, you have to literally think like one. , ... are more likely to stick with it rather than invest ... student at the University of Wisconsin-Milwaukee (UWM). , Flanigan ... bees as they gather pollen ?which plant species the bees ...
... five-year, $1 million grant from the National Cancer Institute, a ... improve the effectiveness of a drug that he developed ... Waldemar Debinski, M.D., Ph.D., pioneered a method to destroy cells ... The drug is currently being tested in clinical trials and ...
... research team led by scientists at the Broad Institute of ... kind of genetic "roadmap" that can connect human diseases with ... new drugs work in human cells. Called the "Connectivity Map," ... September 29 issue of Science and in separate publications in ...
Cached Biology News:Researchers find that bumblebees' flower choice matters 2Researchers find that bumblebees' flower choice matters 3Researchers find that bumblebees' flower choice matters 4Scientist works to improve treatment for brain tumors 2Genetic 'roadmap' charts links between drugs and human disease 2Genetic 'roadmap' charts links between drugs and human disease 3
SCCRO (S-17)...
...
... Blasticidin is a ... griseochromogenes. It is a ... both prokaryotic and eukaryotic ... is conferred by the ...
... 15(S)-15-methyl PGF2α is a ... It is a potent uterine ... be administered intramuscularly to induce ... reduces serum progesterone concentrations when ...
Biology Products: